Aurobindo Pharma moves up on aiming to complete Pen G plant in Andhra Pradesh by March 2024
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 463.60, up by 2.90 points or 0.63% from its previous closing of Rs. 460.70 on the BSE.
The scrip opened at Rs. 461.05 and has touched a high and low of Rs. 464.85 and Rs. 461.05 respectively. So far 5545 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 457.20 on 14-Nov-2022.
Last one week high and low of the scrip stood at Rs. 483.40 and Rs. 459.05 respectively. The current market cap of the company is Rs. 27161.18 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 37.97% and 10.20% respectively.
Aurobindo Pharma is aiming to complete its Rs 2,000 crore Penicillin G (Pen G) plant in Andhra Pradesh by March 2024 even as the trial or the pilot batches will take place starting October next year onwards. Out of Rs 2000 crore, the drug maker has already spent around Rs 500 crore and Rs 1,500 crore is going to be spent in the coming year.
The production capacity of the plant will be around 15,000 tonnes annually. The plant been approved under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
